Literature DB >> 315220

Late results of extra-anatomic bypass.

J J Livesay, J B Atkinson, J D Baker, R W Busuttil, W F Barker, H I Machleder.   

Abstract

Clinical progress and results were reviewed in 100 consecutive patients who underwent extra-anatomic bypass procedures for brachiocephalic and aortoiliac occlusive disease during the past 15 years. Of 113 procedures in this group, extra-anatomic bypass of the brachiocephalic vessels, axillo-femoral bypass, and femorofemoral bypass were performed. Although these procedures were performed in high-risk patients to avoid intrathoracic and intra-abdominal reconstruction or to circumvent undesirable anatomic areas, a low operative mortality was achieved. Symptomatic improvement, augmented Doppler ankle pressure index, and high limb-salvage rate were noted. Life-table analysis has confirmed prolonged five-year graft patency. The suspected high-risk characteristic in this group was corroborated by high progressive mortality observed particularly after axillo-femoral bypass and was due primarily to the severity of associated diseases. Analysis of the late results of extraanatomic bypass confirms the safety and effectiveness of this procedure in poor-risk patients.

Entities:  

Mesh:

Year:  1979        PMID: 315220     DOI: 10.1001/archsurg.1979.01370350062006

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Supraceliac aorta-to-femoral artery bypass: definitive treatment for failed axillary femoral bypass.

Authors:  D A Ott; S M Sethi
Journal:  Tex Heart Inst J       Date:  1984-06

Review 2.  Extraanatomical bypass procedures.

Authors:  F W Blaisdell
Journal:  World J Surg       Date:  1988-12       Impact factor: 3.352

3.  A review of 155 extra-anatomic bypass grafts.

Authors:  M C Foster; T Mikulin; B R Hopkinson; G S Makin
Journal:  Ann R Coll Surg Engl       Date:  1986-07       Impact factor: 1.891

4.  Effect of external pressure on axillofemoral bypass grafts.

Authors:  M V Jarowenko; D Buchbinder; D M Shah
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.